Table 2.

Pain reliever use of participants in the NCI Maryland Prostate Cancer Case-Control Study

CasesaPopulation controls
All (n = 823)AA (n = 422)EA (n = 401)All (n = 1,034)AA (n = 486)EA (n = 548)
Regular aspirinb usec, N (%)
 No418 (51)244 (58)174 (43)446 (43)236 (49)210 (38)
 Yes405 (49)178 (42)227 (57)588 (57)250 (51)338 (62)
Regular aspirin use 1 year prior to interview, N (%)
 No418 (51)244 (58)174 (43)446 (43)236 (49)210 (38)
 Yes354 (43)151 (36)203 (51)534 (52)221 (45)313 (57)
 Did not provide51 (6)27 (6)24 (6)54 (5)29 (6)25 (5)
In the past 5 years, did you take at least 1 tablet daily? N (%)
 No435 (53)254 (60)181 (45)472 (46)245 (50)227 (41)
 Yes387 (47)168 (40)219 (55)561 (54)240 (49)321 (59)
 Did not provide1111 (<1)
In the past 5 years, how long did you regularly take aspirin? N (%)
 Did not use418 (51)244 (58)174 (43)446 (43)236 (49)210 (38)
 ≤3 years148 (18)72 (17)76 (19)177 (17)90 (18)87 (16)
 >3 years251 (30)103 (24)148 (37)403 (39)157 (32)246 (45)
 Did not provide6 (1)3 (1)3 (1)8 (1)3 (1)5 (1)
Regular Tylenol use, N (%)
 No763 (93)395 (94)368 (92)962 (93)463 (95)499 (91)
 Yes59 (7)26 (6)33 (8)72 (7)23 (5)49 (9)
 Did not provide1 (<1)1 (<1)
Regular pain relieverd use, N (%)
 No686 (83)362 (86)324 (81)916 (89)450 (93)466 (85)
 Yes137 (17)60 (14)77 (19)118 (11)36 (7)82 (15)
  • aCases recruited within 1 year after disease diagnosis with an average interval between diagnosis and enrollment of 4.8 months.

  • bAspirin or aspirin-containing compounds such as Bufferin, Anacin, Ascriptin, and Exedrin.

  • cRegular use of pain relievers is defined as taking pain relievers at least 1 per week for 2 months during the past 5 years.

  • dPain reliever not containing aspirin, aspirin-containing compounds, or Tylenol.